生脉注射液诱导心肌组织内干细胞分化与体外循环心肌保护
|
摘要
以往认为,心脏为终末分化器官,其细胞本身不具有增殖分化功能,因此无法修复损伤心肌。但随着细胞生物学技术的进步以及人们研究的深入,心脏中存在心肌干细胞(CSC)的观念已经越来越多地为医学工作者们所接受。本研究将含不同浓度生脉注射液的培养基用于培养心肌组织来源细胞,观察该药能否在体外诱导心肌组织内干细胞分化,并通过临床试验进一步证实生脉注射液具有减轻心肌缺血-再灌注损伤的作用,同时探讨其体外循环心肌保护作用是否与诱导心肌组织内干细胞分化存在关联。
第一部分生脉注射液促进人心肌组织内干细胞分化为心肌细胞的体外实验
目的：成功培养人心肌组织来源细胞,尝试提取人CSC,观察生脉注射液是否具有诱导干细胞分化的作用,为后期的临床研究奠定基础；
方法：选择行心脏手术的病人,将术中切除的心肌组织保留,用组织块消化法提取细胞,通过体外扩增后用免疫磁珠法分选人心肌组织来源干细胞,并尝试用不同浓度生脉注射液干预细胞,利用免疫荧光的方法检测心肌特异性转录因子和心肌特异性蛋白,进一步验证生脉注射液的诱导干细胞分化作用；
结果：从人心肌组织中成功提取细胞,并在体外扩增,但未能成功分选人CSC,免疫荧光法证实5μl/ml和10μl/ml生脉注射液可以诱导心肌组织内干细胞分化,浓度增大后诱导效率稍有下降；结论：适当浓度的生脉注射液可以诱导心肌组织内干细胞分化为心肌细胞,但由于CSC本身含量极低,因此未能成功将其分选出来。
第二部分生脉注射液在体外循环心肌保护中的作用
目的：通过临床研究,证实生脉注射液可以减轻体外循环诱发的缺血再灌注损伤,观察体内试验中生脉注射液是否可以诱导心肌组织内干细胞分化为心肌组织；方法：选择行心脏手术的病人,分别选择术前、术中及术后的六个时间点抽取血液,检测血清中SOD、MDA、cTnl和CK-MB水平,术中切除小块心肌组织,用免疫荧光的方法检测其中心肌特异性转录因子(GATA4、Nkx2.5)和特异性蛋白(Cx 43、cTnI);结果：入院时两组患者血清SOD活力、MDA水平无明显差异,而手术开始时试验组血清SOD活力显著高于对照组,术后一天时试验组血清MDA水平显著低于对照组,而试验组和对照组血清cTnI和CK-MB水平有显著差异；试验组GATA-4和NKx2.5荧光强度显著强于对照组,试验组的cTnT和Cx43仍然趋向较强的荧光信号,但无显著统计学差异；结论：生脉注射液可以增强血清中SOD活力及减少脂质过氧化反应,抑制体外循环过程中的缺血再灌注损伤,而心肌组织内干细胞分化为心肌细胞可能也参与了体外循环心肌保护。
第三部分我国大陆地区主动脉夹层发病特征——文献综合分析及与主动脉夹层国际注册研究资料进行对比
目的：急性主动脉夹层(AAD)是一种致死率和致残率高的临床急症。为了加深对该病的认识,提高诊治水平,国际主动脉夹层注册研究(IRAD)于1996年成立。中国大陆(MC)是世界上人口最多的地区,每年新发AAD病人越来越多,由于IRAD病例均来源于发达的西方国家,医疗体制、经济发展水平和人种都与MC有所不同,因此该病在IRAD和MC两个群体之间的差异可能被忽略。
方法：我们通过检索PubMed数据库和中国全文期刊数据库,通过一定的标准,分别选取了来自IRAD和MC的临床报告,以求助或者购买来获得全文。根据数据性质不同,分别采用t检验、卡方检验或Fisher精确概率计算等方法进行统计,所有统计过程应用SPSS 13.0软件进行。
结果：来自MC的AAD病人较IRAD组病人显著年轻,且前者中男性病人比例也高于后者(80.7% vs 68.6%,P<0.001)。中国病人更可能出现非典型症状和体征。与IRAD相比,中国医师更愿意选择磁共振来进行AAD的诊断(45.5% vs 11.6%,P<0.001)。总体上来说,两组住院期间死亡率类似,但是由于研究方法的限制,相当一部分来自MC的病例未能参与统计,并且中国病人接受治疗的比例也较低。
结论：通过初步观察和分析,我们可以发现IRAD和MC之间在AAD临床特征上存在一定的差异,但是这些结果需要更深入细致地研究加以证实。
In the past, the adult heart had been regarded as terminally differentiated organ, cells isolated from which did not have the capability of generation and differentiation. With the development of technology in cell biology and studying much further, the opinion that there are a cluster of cells with the characteristics of stem cells in the heart have been accepted. In this study, four kinds of cell culture medium containing different concentration of Shengmai injection were used for cell expansion in order to assess whether Shengmai injection could induce stem cells in myocardium to differentiate into cardiomyocytes. Then a clinical trial would be carried out to confirm that Shengmai injection was able to extenuate myocardium ischemical reperfusion injury and to explore the ralationship between cardiac stem cells (CSC) differentiation and myocardial preservation in cardiopulmonary bypass.
Part one Shengmai injection inducing the stem cells in myocardium to differentiate into cardiomyocytes in vitro
Objective To isolate cells from myocardium and try to abstract cardiac stem cells, then assess whether Shengmai injection could induce stem cells in myocardium to differentiate into cardiomyocytes.
Methods After patients'written consent, myocardium discarded in cardiac operation were collected and digested to dissociate and extract heart cells. A few weeks later, the cells were expanded and used to separate the stem cells by the way of immunomagnetic beads sorting. Then four kinds of cell culture medium containing different concentration of Shengmai injection were applied to induce stem cells in myocardium to differentiate into cardiomyocytes and the specificity transcription factors and protein of cardiomyocytes were detected by the method of immunocytochemical staining.
Results Heart cells were isolated and expand in vitro successfully and the cell culture medium containing concentration of 5μl/ml and 10μl/ml Shengmai injection could induce stem cells in myocardium to differentiate into cardiomyocytes, but regrettably the cardiac stem cells were not able to sort from heart cells.
Conclusion The cell culture medium containing appropriate concentration can induce stem cells in myocardium to differentiate into cardiomyocytes, but the cardiac stem cells were not able to sort from heart cells because of their much low number.
Part Two Shengmai performing myocardia) protection during cardiopulmonary bypass
Objective To comfirm that Shengmai injection can extenuate ischemia-reperfusion injury caused by cardiopulmonary bypass and determine whether Shengmai injection could induce stem cells in myocardium to differentiate into cardiomyocytes in vivo.
Methods After patients'written consent, six blood samples were acquired at six time points in perioperative period which were used to test the contents of SOD、MDA、cTnl and CK-MB in serum. A small size of myocardium was taken in every patient and cardiac-specific transcription factors(GATA4、Nkx2.5)and cardiac-specific proteins(Cx 43、cTnI) were detected by the method of immunocytochemical staining.
Results There was no significantly difference in serum SOD activity and MDA content between the two groups on admission. But before operation, serum SOD activity was significantly higher in the experimental group and in the day after surgery serum MDA level was significantly lower than that in the control group. And Serum cTnl and CK-MB levels were significantly different between the experimental and control group. Fluorescence intensity of NKx2.5 GATA-4 in the experimental group was significantly stronger than that of the control group, and fluorescence intensity of cTnT and Cx43 in experimental group was also stronger than that of the control group but no significant difference.
Conclusion Shengmai injection could enhance the SOD activity and inhibit lipid peroxidation which extenuate ischemia-reperfusion injury caused by cardiopulmonary bypass during. Stem cells in myocardium differentiation into cardiomyocytes might also be involved in myocardial protection during cardiopulmonary bypass.
Part three Preliminary characterization of acute aortic dissection in Mainland China——Comprehensive analysis of the literature in comparison with the International Registry of Acute Aortic Dissection (IRAD)
Objective Acute aortic dissection (AAD) is a clinical emergencies with high morbidity and mortality. In order to more fully understand the characteristics of AAD, the International Registry of Acute Aortic Dissection (IRAD) was established but the registry had only enrolled cases from developed countries, which could not be sufficient to know the full extent of this condition. And there may also be some differences in the characteristics of AAD between IRAD countries and Mainland China(MC).
Methods Reports from IRAD and MC were collected by searching in the PubMed Databases and the Chinese Journal Full-text Database, and patients'data were abstracted. The 2 groups were compared using the chi-square test, Fisher's exact test and Student's t test as appropriate.
Results AAD patients from MC were significantly younger than IRAD and the percentage of male patients in the Chinese group was higher than IRAD (80.7% vs 68.6%, P<0.001). Patients in MC were less likely to present with typical symptoms and signs except for any focal neurological deficits. Different from the IRAD group, Chinese patients were prone to undergo magnetic resonance imaging (MRI) to make the diagnosis of AAD (45.5% vs 11.6%, P<0.001). The in-hospital mortality was similar between 2 groups but only smaller proportion of AAD patients in MC underwent surgical or medical treatment.
Conclusions From this paper, the general characteristics of AAD patients in MC were shown and differences in some clinical variables between MC and IRAD groups still existed. However, the results need to be proved by much further studies.
第一部分生脉注射液促进人心肌组织内干细胞分化为心肌细胞的体外实验
目的：成功培养人心肌组织来源细胞,尝试提取人CSC,观察生脉注射液是否具有诱导干细胞分化的作用,为后期的临床研究奠定基础；
方法：选择行心脏手术的病人,将术中切除的心肌组织保留,用组织块消化法提取细胞,通过体外扩增后用免疫磁珠法分选人心肌组织来源干细胞,并尝试用不同浓度生脉注射液干预细胞,利用免疫荧光的方法检测心肌特异性转录因子和心肌特异性蛋白,进一步验证生脉注射液的诱导干细胞分化作用；
结果：从人心肌组织中成功提取细胞,并在体外扩增,但未能成功分选人CSC,免疫荧光法证实5μl/ml和10μl/ml生脉注射液可以诱导心肌组织内干细胞分化,浓度增大后诱导效率稍有下降；结论：适当浓度的生脉注射液可以诱导心肌组织内干细胞分化为心肌细胞,但由于CSC本身含量极低,因此未能成功将其分选出来。
第二部分生脉注射液在体外循环心肌保护中的作用
目的：通过临床研究,证实生脉注射液可以减轻体外循环诱发的缺血再灌注损伤,观察体内试验中生脉注射液是否可以诱导心肌组织内干细胞分化为心肌组织；方法：选择行心脏手术的病人,分别选择术前、术中及术后的六个时间点抽取血液,检测血清中SOD、MDA、cTnl和CK-MB水平,术中切除小块心肌组织,用免疫荧光的方法检测其中心肌特异性转录因子(GATA4、Nkx2.5)和特异性蛋白(Cx 43、cTnI);结果：入院时两组患者血清SOD活力、MDA水平无明显差异,而手术开始时试验组血清SOD活力显著高于对照组,术后一天时试验组血清MDA水平显著低于对照组,而试验组和对照组血清cTnI和CK-MB水平有显著差异；试验组GATA-4和NKx2.5荧光强度显著强于对照组,试验组的cTnT和Cx43仍然趋向较强的荧光信号,但无显著统计学差异；结论：生脉注射液可以增强血清中SOD活力及减少脂质过氧化反应,抑制体外循环过程中的缺血再灌注损伤,而心肌组织内干细胞分化为心肌细胞可能也参与了体外循环心肌保护。
第三部分我国大陆地区主动脉夹层发病特征——文献综合分析及与主动脉夹层国际注册研究资料进行对比
目的：急性主动脉夹层(AAD)是一种致死率和致残率高的临床急症。为了加深对该病的认识,提高诊治水平,国际主动脉夹层注册研究(IRAD)于1996年成立。中国大陆(MC)是世界上人口最多的地区,每年新发AAD病人越来越多,由于IRAD病例均来源于发达的西方国家,医疗体制、经济发展水平和人种都与MC有所不同,因此该病在IRAD和MC两个群体之间的差异可能被忽略。
方法：我们通过检索PubMed数据库和中国全文期刊数据库,通过一定的标准,分别选取了来自IRAD和MC的临床报告,以求助或者购买来获得全文。根据数据性质不同,分别采用t检验、卡方检验或Fisher精确概率计算等方法进行统计,所有统计过程应用SPSS 13.0软件进行。
结果：来自MC的AAD病人较IRAD组病人显著年轻,且前者中男性病人比例也高于后者(80.7% vs 68.6%,P<0.001)。中国病人更可能出现非典型症状和体征。与IRAD相比,中国医师更愿意选择磁共振来进行AAD的诊断(45.5% vs 11.6%,P<0.001)。总体上来说,两组住院期间死亡率类似,但是由于研究方法的限制,相当一部分来自MC的病例未能参与统计,并且中国病人接受治疗的比例也较低。
结论：通过初步观察和分析,我们可以发现IRAD和MC之间在AAD临床特征上存在一定的差异,但是这些结果需要更深入细致地研究加以证实。
In the past, the adult heart had been regarded as terminally differentiated organ, cells isolated from which did not have the capability of generation and differentiation. With the development of technology in cell biology and studying much further, the opinion that there are a cluster of cells with the characteristics of stem cells in the heart have been accepted. In this study, four kinds of cell culture medium containing different concentration of Shengmai injection were used for cell expansion in order to assess whether Shengmai injection could induce stem cells in myocardium to differentiate into cardiomyocytes. Then a clinical trial would be carried out to confirm that Shengmai injection was able to extenuate myocardium ischemical reperfusion injury and to explore the ralationship between cardiac stem cells (CSC) differentiation and myocardial preservation in cardiopulmonary bypass.
Part one Shengmai injection inducing the stem cells in myocardium to differentiate into cardiomyocytes in vitro
Objective To isolate cells from myocardium and try to abstract cardiac stem cells, then assess whether Shengmai injection could induce stem cells in myocardium to differentiate into cardiomyocytes.
Methods After patients'written consent, myocardium discarded in cardiac operation were collected and digested to dissociate and extract heart cells. A few weeks later, the cells were expanded and used to separate the stem cells by the way of immunomagnetic beads sorting. Then four kinds of cell culture medium containing different concentration of Shengmai injection were applied to induce stem cells in myocardium to differentiate into cardiomyocytes and the specificity transcription factors and protein of cardiomyocytes were detected by the method of immunocytochemical staining.
Results Heart cells were isolated and expand in vitro successfully and the cell culture medium containing concentration of 5μl/ml and 10μl/ml Shengmai injection could induce stem cells in myocardium to differentiate into cardiomyocytes, but regrettably the cardiac stem cells were not able to sort from heart cells.
Conclusion The cell culture medium containing appropriate concentration can induce stem cells in myocardium to differentiate into cardiomyocytes, but the cardiac stem cells were not able to sort from heart cells because of their much low number.
Part Two Shengmai performing myocardia) protection during cardiopulmonary bypass
Objective To comfirm that Shengmai injection can extenuate ischemia-reperfusion injury caused by cardiopulmonary bypass and determine whether Shengmai injection could induce stem cells in myocardium to differentiate into cardiomyocytes in vivo.
Methods After patients'written consent, six blood samples were acquired at six time points in perioperative period which were used to test the contents of SOD、MDA、cTnl and CK-MB in serum. A small size of myocardium was taken in every patient and cardiac-specific transcription factors(GATA4、Nkx2.5)and cardiac-specific proteins(Cx 43、cTnI) were detected by the method of immunocytochemical staining.
Results There was no significantly difference in serum SOD activity and MDA content between the two groups on admission. But before operation, serum SOD activity was significantly higher in the experimental group and in the day after surgery serum MDA level was significantly lower than that in the control group. And Serum cTnl and CK-MB levels were significantly different between the experimental and control group. Fluorescence intensity of NKx2.5 GATA-4 in the experimental group was significantly stronger than that of the control group, and fluorescence intensity of cTnT and Cx43 in experimental group was also stronger than that of the control group but no significant difference.
Conclusion Shengmai injection could enhance the SOD activity and inhibit lipid peroxidation which extenuate ischemia-reperfusion injury caused by cardiopulmonary bypass during. Stem cells in myocardium differentiation into cardiomyocytes might also be involved in myocardial protection during cardiopulmonary bypass.
Part three Preliminary characterization of acute aortic dissection in Mainland China——Comprehensive analysis of the literature in comparison with the International Registry of Acute Aortic Dissection (IRAD)
Objective Acute aortic dissection (AAD) is a clinical emergencies with high morbidity and mortality. In order to more fully understand the characteristics of AAD, the International Registry of Acute Aortic Dissection (IRAD) was established but the registry had only enrolled cases from developed countries, which could not be sufficient to know the full extent of this condition. And there may also be some differences in the characteristics of AAD between IRAD countries and Mainland China(MC).
Methods Reports from IRAD and MC were collected by searching in the PubMed Databases and the Chinese Journal Full-text Database, and patients'data were abstracted. The 2 groups were compared using the chi-square test, Fisher's exact test and Student's t test as appropriate.
Results AAD patients from MC were significantly younger than IRAD and the percentage of male patients in the Chinese group was higher than IRAD (80.7% vs 68.6%, P<0.001). Patients in MC were less likely to present with typical symptoms and signs except for any focal neurological deficits. Different from the IRAD group, Chinese patients were prone to undergo magnetic resonance imaging (MRI) to make the diagnosis of AAD (45.5% vs 11.6%, P<0.001). The in-hospital mortality was similar between 2 groups but only smaller proportion of AAD patients in MC underwent surgical or medical treatment.
Conclusions From this paper, the general characteristics of AAD patients in MC were shown and differences in some clinical variables between MC and IRAD groups still existed. However, the results need to be proved by much further studies.
引文
[1]Cohn LH. "Fifty years of open-heart surgery".[J] Circulation 2003;107(17):2168-2170.
[2]Braunwald E, Kloner RA. Myocardial reperfusion:a double-edged sword?[J] J Clin Invest 1985;76(5): 1713-1719.
[3]Yellon DM, Baxter GF. Protecting the ischaemic and reperfused myocardium in acute myocardial infarction:distant dream or near reality?[J] Heart 2000;83(4):381-387.
[4]Lazzarino G, Raatikainen P, Nuutinen M, et al. Myocardial release of malondialdehyde and purine compounds during coronary bypass surgery.[J] Circulation 1994;90(1):291-297.
[5]Piper HM, Meuter K, Schafer C. Cellular mechanisms of ischemia-reperfusion injury.[J]Ann Thorac Surg 2003;75(2):S644-S648.
[6]Gross GJ,Kersten JR,Warltier DC. Mechanisms of postischemic contractile dysfunction.[J]Ann Thorac Surg 1999;68(5):1898-1904.
[7]Neves LA, Almeida AP, Khosla MC, et al. Effect of angiotensin-(1-7)on reperfusion arrhythmias in isolated rat hearts.[J] Braz J Med Biol Res 1997;30(6):801-809.
[8]Kloner RA, Giacomelli F, Alker KJ, et al. Influx of neutrophils into the walls of large epicardial coronary arteries in response to ischemia/reperfusion.[J] Circulation 1991;84(4):1758-1772.
[9]Xiao CY, Hara A, Yuhki K, et al. Roles ofprostaglandin I(2)and thromboxane A(2)in cardiac ischemia-reperfusion injury:a study using mice lacking their respective receptors.[J]Circulation 2001;104(18): 2210-2215.
[10]Heyndrickx GR, Millard RW, McRitchie RJ, et al. Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs.[J] J Clin Invest 1975;56(4):978-985.
[11]Kloner RA, Arimie RB, Kay GL, et al. Evidence for stunned myocardium in humans:a 2001 update.[J] Coron Artery Dis 2001;12(5):349-356.
[12]Manning AS, Hearse DJ. Reperfusion-induced arrhythmias:mechanisms and prevention.[J] J Mol Cell Cardiol 1984; 16(6):497-518.
[13]Meerson FZ, Belkina LM, Sazontova TG, et al. The role of lipid peroxidation in pathogenesis of arrhythmias and prevention of cardiac fibrillation with antioxidants.[J] Basic Res Cardiol 1987;82(2):123-137.
[14]Piper HM, Meuter K, Schafer C. Cellular mechanisms of ischemia-reperfusion injury.[J] Ann Thorac Surg 2003;75(2):S644-S648.
[15]Ku DD. Coronary vascular reactivity after acute myocardial ischemia.[J] Science 1982;218(4572): 576-578.
[16]Lefer AM, Lefer DJ. The role of nitric oxide and cell adhesion molecules on the microcirculation in ischaemia-reperfusion.[J] Cardiovasc Res 1996;32(4):743-751.
[17]Canbaz S, Duran E, Ege T, et al. The effects of intracoronary administration of vitamin E on myocardial ischemia-reperfusion injury during coronary artery surgery.[J] Thorac Cardiovasc Surg 2003;51(2):57-61.
[18]Li XS, Uriuda Y, Wang QD, et al. Role of 1-arginine in preventing myocardial and endothelial injury following ischaemia/reperfusion in the rat isolated heart.[J] Acta Physiol Scand 1996; 156(1):37-44.
[19]Lerman A, Burnett Jr JC, Higano ST, et al. Long-term 1-arginine supplementation improves small-vessel coronary endothelial function in humans.[J] Circulation 1998;97(21):2123-2128.
[20]Rodriguez-Sinovas A, Garcia-Dorado D, Padilla F, et al. Pre-treatment with the Na+/H+exchange inhibitor cariporide delays cell-to-cell electrical uncoupling during myocardial ischemia.[J] Cardiovasc Res 2003;58(l): 109-117.
[21]Garcia-Dorado D, Theroux P, Duran JM, et al. Selective inhibition of the contractile apparatus.A new approach to modification of infarct size, infarct composition, and infarct geometry during coronary artery occlusion and reperfusion.[J] Circulation 1992;85(3):1160-1174.
[22]李勤,刘宏.生脉注射液的药理作用及临床应用.[J]医学综述2005；11(10)：950-951.
[23]蒙定水,孙素红,甘照儒,等.生脉注射液对心肺复苏兔心肌细胞的作用及应用时机的研究.[J]广西中医药2005；28(4)：45-47.
[24]尹旭斌.生脉合复方丹参注射液治疗急性病毒性心肌炎40例.[J]中国中医急症2002；11(5)：380.
[25]张西联,黄跃生,党永明,等.生脉注射液对大鼠烧伤后心肌细胞凋亡的影响.[J]第三军医大学学报2007；29(2)：94-96.
[26]张亚臣,陈捷,吕宝经,等.生脉注射液对肥厚心肌超微结构和钙泵功能的影响.[J]上海第二医科大学学报2005；25(10)：1022-1024.
[27]吕宝经,张亚臣,郑宏超,等.左室造影评价生脉注射液改善冠心病患者心功能的作用.[J]中国临床药学杂志2005,14(4)：207-209.
[28]党波,商惠萍,江丽.生脉注射液对冠心病患者内皮功能的影响.[J]陕西中医2005；26(7)：639-640.
[29]侯智亮.生脉注射液对心脏手术心肌保护作用的临床观察.[J]中国现代医生2010；48(1)：51-52.
[30]何涛,张红星,高清元.生脉注射液在心脏直视手术中对心肌缺血再灌注损伤的保护作用.[J]临床医药实践2005；14(1)：28-29.
[31]Leri A, Kajstura J, Anversa P. Cardiac stem cells and mechanisms of myocardial regeneration.[J] Physiol Rev 2005; 85(4):1373-1416.
[32]Itzhaki-Alfia A, Leor J, Raanani E, et al. Patient characteristics and cell source determine the number of isolated human cardiac progenitor cells.[J] Circulation 2009; 120(25):2559-2566.
[33]Smits AM, van Vliet P, Metz CH, et al. Human cardiomyocyte progenitor cells differentiate into functional mature cardiomyocytes:an in vitro model for studying human cardiac physiology and pathophysiology.[J] Nat Protoc 2009; 4(2):232-43.
[34]姜宏,施广飞.心肌干细胞培养和纯化的实验方法研究.[J]现代生物医学进展2009；9(1)：33-35.
[35]姜宏,施广飞.5-氮胞苷诱导心肌组织中c-kit+干细胞分化的实验研究.[J]中国临床药理学与治疗学2008；13(9)：996-1001.
[36]Tomita Y, Makino S, Hakuno D, et al. Application of mesenchymalstem cell-derived cardiomyocytes as bio-pacemakers:current s tatus and problems to be solved.[J] Med Biol Eng Comput 2007;45(2):209-220.
[1]Leri A, Kajstura J, Anversa P. Cardiac stem cells and mechanisms of myocardial regeneration.[J] Physiol Rev,2005; 85(4):1373-416.
[2]Itzhaki-Alfia A, Leor J, Raanani E, et al. Patient characteristics and cell source determine the number of isolated human cardiac progenitor cells.[J] Circulation,2009; 120(25):2559-66.
[3]Smits AM, van Vliet P, Metz CH, et al. Human cardiomyocyte progenitor cells differentiate into functional mature cardiomyocytes:an in vitro model for studying human cardiac physiology and pathophysiology.[J] Nat Protoc,2009; 4(2):232-43.
[4]Leri A, Kajstura J, Anversa P. Cardiac stem cells and mechanisms of myocardial regeneration.[J] Physiol Rev,2005; 85(4):1373-416.
[5]Holmes C, Stanford WL. Concise review:stem cell antigen-1:expression, function, and enigma.[J] Stem Cells,2007; 25(6):1339-47.
[6]Urbanek K, Torella D, Sheikh F, et al. Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure.[J] Proc Natl Acad Sci USA,2005; 102(24):8692-8697.
[7]汪朝晖,冼绍祥,杨忠奇,等.人参总皂苷诱导骨髓间充质干细胞分化为心肌细胞的实验研究.[J]广州中医药大学学报,2006；23(2)：100-103.
[8]杨忠奇,冼绍祥,汪朝晖,等.三七总皂苷对骨髓间充质干细胞分化为心肌样细胞的作用.[J]中药新药与临床药理,2006；17(4)：239-242。
[9]冼绍祥,杨忠奇,汪朝晖,等.黄芪甲苷体外诱导骨髓间充质干细胞分化为心肌样细胞的实验研究.[J]广州中医药大学学报,2007；24(1)：37-40.
[10]杨庆有,冼绍祥,孙慧茹,等.黄芪含药血清诱导骨髓间充质干细胞分化为心肌样细胞的实验研究.[J]辽宁中医杂志,2008；35(6)：832-834.
[11]谢玲玲.淫羊藿苷诱导骨髓间充质干细胞分化心肌样细胞的实验研究.[D]广州：广州中医药大学中西医结合基础专业,2008.
[12]罗明凤,张三印,黄秀深,等.参附注射液和生脉注射液对心肌细胞Ca2+-ATP酶影响的对比研究.[J]天津中医药,2008；25(6)：487-490.
[13]陈海霞,王晓春,张阳德,等.生脉注射液对人骨髓造血细胞增殖作用的研究.[J]中国实用内科杂志,2006；26(2)：118-120.
[1]Yellon DM,Baxter GF. Protecting the ischaemic and reperfused myocardium in acute myocardial infarction:distant dream or near reality?[J] Heart 2000;83(4):381-387.
[2]Nicolini F, Beghi C, Muscari C, et al. Myocardial protection in adult cardiac surgery:current options and future challenges.[J] Eur J Cardiothorac Surg 2003; 24(6):986-993.
[3]豆利华.丹参酮ⅡA磺酸钠在体外循环心脏直视术中缺血早期心肌保护作用及对IMA、GPBB水平的影响.[J]河北医药2010；32(17)：2327-2329.
[4]顾家珍,李俊,刘世清,等.心内直视手术中复方丹参的心肌保护作用.[J]中国中西医结合杂志1998；18(2)：68-70.
[5]侯智亮.生脉注射液对心脏手术心肌保护作用的临床观察.[J]中国现代医生2010；48(1)：51-52.
[6]吕民,姜亦忠,张秀和,等.生脉注射液对心肌缺血与再灌注损伤的保护作用.[J]吉林大学学报(医学版)2005；31(3)：446-448.
[7]Cohn LH."Fifty years of open-heart surgery".[J] Circulation 2003;107(17):2168-2170.
[8]Braunwald E,Kloner RA.Myocardial reperfusion:a double-edged sword?.[J] J Clin Invest 1985;76(5):1713-1719.
[9]Jennings RB, Sommers HM, Smyth GA, et al. Myocardial necrosis induced by temporary occlusion of a coronaryartery in the dog.[J] Arch Pathol 1960;70:68-78.
[10]Bulkley BH. Myocardial consequences of coronary artery bypass graft surgery:the paradox of necrosis in areas of revascularization.[J] Circulation 1977;56(6):906-913.
[11]Lazzarino G, Raatikainen P, Nuutinen M, et al. Myocardial release of malondialdehyde and purine compounds during coronary bypass surgery.[J] Circulation 1994;90(1):291-297.
[12]Piper HM, Meuter K, Schafer C. Cellular mechanisms of ischemia-reperfusion injury.[J]Ann Thorac Surg 2003;75(2):S644-S648.
[13]Gross GJ,Kersten JR,Warltier DC. Mechanisms of postischemic contractile dysfunction.[J]Ann Thorac Surg 1999;68(5):1898-1904.
[14]Neves LA, Almeida AP, Khosla MC, et al. Effect of angiotensin-(1-7)on reperfusion arrhythmias in isolated rat hearts.[J] Braz J Med Biol Res 1997;30(6):801-809.
[15]Kloner RA, Giacomelli F, Alker KJ, et al. Influx of neutrophils into the walls of large epicardial coronary arteries in response to ischemia/reperfusion.[J] Circulation 1991;84(4):1758-1772.
[16]Xiao CY, Hara A, Yuhki K, et al. Roles ofprostaglandin I(2)and thromboxane A(2)in cardiac ischemia-reperfusion injury:a study using mice lacking their respective receptors.[J] Circulation 2001;104(18): 2210-2215.
[17]Canbaz S, Duran E, Ege T, et al. The effects of intracoronary administration of vitamin E on myocardial ischemia-reperfusion injury during coronary artery surgery.[J] Thorac Cardiovasc Surg 2003;51(2):57-61.
[18]Li XS, Uriuda Y, Wang QD, et al. Role of 1-arginine in preventing myocardial and endothelial injury following ischaemia/reperfusion in the rat isolated heart.[J] Acta Physiol Scand 1996;156(1):37-44.
[19]Lerman A, Burnett Jr JC, Higano ST, et al. Long-term 1-arginine supplementation improves small-vessel coronary endothelial function in humans.[J] Circulation 1998;97(21):2123-2128.
[20]Rodriguez-Sinovas A, Garcia-Dorado D, Padilla F, et al. Pre-treatment with the Na+/H+exchange inhibitor cariporide delays cell-to-cell electrical uncoupling during myocardial ischemia.[J] Cardiovasc Res 2003;58(l): 109-117.
[21]Garcia-Dorado D, Theroux P, Duran JM, et al. Selective inhibition of the contractile apparatus.A new approach to modification of infarct size, infarct composition, and infarct geometry during coronary artery occlusion and reperfusion.[J] Circulation 1992;85(3):1160-1174.
[22]Maruyama M, Farber NE, Vercellotti GM, et al. Evidence for a role of platelet activating factor in the pathogenesis of irreversible but not reversible myocardial injury after reperfusion in dogs[J]. Am Heart J 1990;120(3):510-520.
[23]Vermeiren GL, Claeys MJ, Van Bockstaele D, et al. Reperfusion injury after focal myocardial ischemia:polymorphonuclear leukocyte activation and its clinical implications[J]. Resuscitation 2000;45(l): 35-61.
[24]周迎春,陈镜合.心肌细胞保护作用的中药研究进展[J].中医药信息2000；17(6)：26-28.
[25]李国虎,陈胜喜,许疗梅,等.生脉心停搏液对体外循环开心手术病人的心肌保护作用[J].湖南医科大学学报1998,23(3)：305-308.
[26]侯智亮.生脉注射液对心脏手术心肌保护作用的临床观察[J].中国现代医生2010；48(1)：51-52.
[27]Lints TJ, Parsons LM, Hartley L, et al. Nkx-2.5:a novel murine homeobox gene expressed in early heart progenitor cells and their myogenic descendants.[J] Development 1993; 119(2):419-431.
[28]Molkentin JD.The zinc finger-containing transcription factors GATA-4,-5, and-6. Ubiquitously expressed regulators of tissue-specific gene expression. J Biol Chem 2000;275(50):38949-38952.
[29]Peterkin T, Gibson A, Loose M, et al. The roles of GATA-4,-5 and-6 in vertebrate heart development. Semin Cell Dev Biol 2005;16(1):83-94.
[30]Davidson SM, Morange M. Hsp25 and the p38 MAPK pathway are involved in differentiation of cardiomyocytes. Dev Biol 2000;218(2):146-160.
[31]Raffin M, Leong LM, Rones MS, et al. Subdivision of the cardiac Nkx2.5 expression domain into myogenic and nonmyogenic compartments. Dev Biol 2000;218(2):326-40.
[32]Panteghini M. Present issues in the determination of troponins and other markers of cardiac damage. Clin Biochem 2000;33(3):161-166.
[33]Moscoso I, centrno A, lopez E, et al.Differentiation "in vitro" of primary and immortalized porcine mesenchymal stem cells into cardiomyocytes for cell transplantation. Transplant Proc 2005;37(1):481-482.
[34]Toyofuku T, Yabubi M, Otsu K, et al. Intercellular calcium signaling via gap junction in connexin-43 transfected cells. J Bio Chem 1998;273(3):1519-1528.
[35]Tomit AS, Schuesslar RB, Berul CI, et al. Disparate effects of deficient expression of connexin-43 on atrial and ventricular conduction. Circulation 1998;97(7):686-691.
[1]秦小奎,刘晓方.113例主动脉夹层的危险因素报告及文献综合分析[J].中华心血管病杂志,2006；34(6)：527-529.
[2]张源明,陈曦,木胡牙提,等.乌鲁木齐市主动脉夹层病例临床特征变化趋势10年回顾性分析[J].中华流行病学杂志,2008；29(7)：720-723.
[3]曾红科,方明,孙诚,等.主动脉夹层累及范围与患者症状关系的临床分析[J].中华心血管病杂志,2004；32(6)：516-518.
[4]薛凌,罗建方,黄文晖,等.主动脉夹层患者临床特征的性别差异[J].中华心血管病杂志,2008；36(5)：415-417.
[5]张源明,周立英,何秉贤,等.主动脉夹层106例的临床分析[J].中华心血管病杂志,2005；33(6)：536-538.
[6]明广华,张宇辉,吴海英,等.179例主动脉夹层患者的临床分析[J].中国循环杂志,2004；19(5)：363-366.
[7]薛凌,罗建方,麦劲壮,等.广州市主动脉夹层临床特征变化趋势十年回顾性分析[J].中华心血管病杂志,2007；35(1)：47-50.
[8]徐冬梅,范崇伦,张梅,等.主动脉夹层106例临床分析[J].山东医药,2003；43(10)：32-33.
[9]周建华,李连镇.主动脉夹层116例临床分析[J].首都医药,2004；18：17-18.
[10]罗勇,王春生,丁文军.38例急性主动脉夹层的临床分析[J].四川大学学报(医学版),2004；35(4)： 589-590.
[11]宋玉娥,王琳,马业新,等.主动脉夹层90例临床分析[J].内科急危重杂志,2004；10(2)：69-71.
[12]Hagan PG, Nienaber CA, Isselbacher EM, et al. The International Registry of Acute Aortic Dissection (IRAD):new insights into an old disease[J]. JAMA,2000; 283(7):897-903.
[13]Golledge J, Eagle KA. Acute aortic dissection[J]. Lancet,2008; 372(9632):55-66.
[14]Collins JS, Evangelista A, Nienaber CA, et al. International Registry of Acute Aortic Dissection (IRAD). Differences in clinical presentation, management, and outcomes of acute type a aortic dissection in patients with and without previous cardiac surgery[J]. Circulation,2004; 110(suppl 1):II237-II242.
[15]Suzuki T, Mehta RH, Ince H, et al. International Registry of Aortic Dissection (IRAD). Clinical profi les and outcomes of acute type B aortic dissection in the current era:lessons from the International Registry of Aortic Dissection (IRAD) [J]. Circulation,2003; 108 (suppl 1):11312-11317.
[16]Tsai TT, Isselbacher EM, Trimarchi S, et al. Acute type B aortic dissection:does aortic arch involvement affect management and outcomes? Insights from the International Registry of Acute Aortic Dissection (IRAD) [J]. Circulation,2007; 116(11 Suppl):1150-1156.
[17]Hirst Jr AE, Johns Jr VJ, Kime Jr SW. Dissecting aneurysm of the aorta:a review of 505 cases[J]. Medicine (Baltimore),1958;37:217-279.
[18]赵秀丽,陈捷,崔艳丽,等.中国14省市高血压现状的流行病学研究[J].中华医学杂志,2006；86(16)：1148-1152.
[19]Centers for Disease Control and Prevention (CDC). Racial/ethnic disparities in p revalence, treatment, and control of hypertension-United States,1999-2002[R]. MMWR Morb MortalWkly Rep,2005;54:7-9.
[20]Yu HY, Chen YS, Huang SC, et al. Late outcome of patients with aortic dissection:study of a national database[J]. Eur J Cardiothorac Surg,2004;25(5):683-690.
[21]Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension:analysis of worldwide data[J]. Lancet,2005;365(9455):217-223.
[22]马冠生,孔灵芝,栾德春,等.中国居民吸烟行为的现状分析[J].中国慢性病预防与控制2005；13(5)：195-199.
[23]Judith M, Michael E. The tobacco control atlas[R]. Geneva:WHO,2002:25-27.
[24]Charbonneau NL, Ono RN, Corson GM, et al. Fine tuning of growth factor signals depends on fibrillin microfibril networks[J]. Birth Defects Res C Embryo Today,2004;72(1):37-50.
[25]Alva JA, Iruela-Arispe ML. Notch signaling in vascular morphogenesis[J]. Curr Opin Hematol,2004; 11(4):278-283.
[26]Cohn LH. Cardiac surgery in the adult.3th Edition[M]. New York:The McGraw-Hill Companies, Inc, 2007.1195-1222.
[27]Tsai TT, Trimarchi S, Nienaber CA. Acute aortic dissection:perspectives from the International Registry of Acute Aortic Dissection (IRAD) [J]. Eur J Vase Endovasc Surg,2009;37(2):149-159.
[28]Angouras D, Sokolis DP, Dosios T, et al. Effect of impaired vasa vasorum flow on the structure and mechanics of the thoracic aorta:implications for the pathogenesis of aortic dissection[J]. Eur J Cardiothorac Surg,2000; 17(4):468-474.
[1]Yellon DM, Baxter GF. Protecting the ischaemic and reperfused myocardium in acute myocardial infarction:distant dream or near reality?[J]. Heart 2000;83(4):381-387.
[2]Nicolini F, Beghi C, Muscari C, et al. Myocardial protection in adult cardiac surgery:current options and future challenges[J]. Eur J Cardiothorac Surg 2003;24(6):986-993.
[3]Jennings RB, Sommers HM, Smyth GA, et al. Myocardial necrosis induced by temporary occlusion of a coronaryartery in the dog[J]. Arch Pathol 1960;70:68-78.
[4]Bulkley BH. Myocardial consequences of coronary artery bypass graft surgery:the paradox of necrosis in areas of revascularization[J]. Circulation 1977;56(6):906-913.
[5]MoensAL,Claeys MJ,Timmermans JP,et al.Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process[J]. Int J Cardiol 2005;100(2):179-190.
[6]Fremes SE, Weisel RD, Mickle DAG, et al. Myocardial metabolism and ventricular function following cold potassium cardioplegia[J]. J Thorac Cardiovasc Surg 1985;89(4):531-546.
[7]Teoh KH, Christakis GT, Weisel RD, et al. Accelerated myocardial metabolic recovery with terminal warm blood cardioplegia(hot shot)[J]. J Thorac Cardiovasc Surg 1986;91(6):888-895.
[8]Ikonomidis JS, Rao V, Weisel RD, et al. Myocardial protection for coronary bypass grafting:The Toronto Hospital perspective[J]. Ann Thorac Surg 1995;60(3):824-832.
[9]Calafiore AM, Teodori G, Mezzetti, et al. Intermittent antegrade warm blood cardioplegia[J]. Ann Thorac Surg 1995;59(2):398-402.
[10]Maruyama M, Farber NE, Vercellotti GM, et al. Evidence for a role of platelet activating factor in the pathogenesis of irreversible but not reversible myocardial injury after reperfusion in dogs[J]. Am Heart J 1990;120(3):510-520.
[11]Vermeiren GL, Claeys MJ, Van Bockstaele D, et al. Reperfusion injury after focal myocardial ischemia:polymorphonuclear leukocyte activation and its clinical implications[J]. Resuscitation 2000;45(l): 35-61.
[12]Ghosh S, Standen NB, Galinanes M. Preconditioning the humanmyocardium by simulated ischemia: studies on the early and delayed protection [J]. Cardiovasc Res 2000;45(2):339-350.
[13]Yellon DM, Baxter GF. Sodium-hydrogen exchange in myocardial reperfusion injury[J]. Lancet 2000;356(9229):522-523.
[14]周迎春,陈镜合.心肌细胞保护作用的中药研究进展[J].中医药信息2000；17(6)：26-28.
[15]Fu GC, Zhang JF, Li YQ., et al. Effects of Sodium ferulate during heart ischemic reperfusion injury in isolate rats[J]. J Henan Med Univ(河南医科大学学报) 1994;29(4):344-346.
[16]洪立明.阿魏酸钠抗实验性心律失常的作用[J].中国药理学通报2002；18(3)：323-325.
[17]句海松,李小洁.阿魏酸钠和18β-苷草次酸对氧自由基的清除作用[J].中国药理学报1999；11(5)：466-470.
[18]谢可鸣,茆勇.阿魏酸钠对小鼠炎性肝损伤的抑制效应及其与ICAM-1和E-selection表达的关系研究[J].中国病理生理杂志2004；20(12)：2330-2335.
[19]傅颖君,何明.阿魏酸钠与心肌保护[J].江西医学院学报2005；45(5)：177-179.
[20]Murry CE, Jennings RB, Peimer KA. Proconditioning withis-chemia:a delay of lethalcell injury in ischemic myocardium[J]. Circulation 1986;74(5):1124-1136.
[21]傅颖君,何明.阿魏酸钠对心肌细胞缺氧/复氧损伤的保护作用及其机制[J].药学学报2004；39(5)：325-327.
[22]刘季春,万力,高涛,等.阿魏酸钠对心内直视手术的心肌保护作用[J].江西医学院学报2007；47(4)：20-25.
[23]高伟,梁日欣,肖永庆等.川芎内酯A预处理对心肌微血管内皮细胞缺氧/复氧损伤保护作用及机制研究[J].中国中药杂志2007；32(2)：133-137.
[24]程伟,易慧智.川芎嗪对大鼠缺血再灌注心肌细胞凋亡的影响[J].中国中医基础医学杂志2007；13(6)：449-450.
[25]陈江斌,唐其柱,孙小梅,等.川芎嗪对复氧后损伤心肌细胞的影响[J].中国现代应用药学2001；18(3)：190-191.
[26]古小明,何明.川芎嗪预处理对心肌细胞缺血/再灌注损伤延迟保护作用[J].广东药学院学报2007；23(2)：183-185.
[27]孙鹏,刘金龙.葛根素对组织缺血再灌注损伤保护机制的研究进展[J].现代中西医结合杂志2006；15(3)：405-407.
[28]吴青,陶宏凯,陶大昌.葛根素对大鼠缺血再灌注心肌细胞保护作用的研究[J].中华现代中西医杂志2004；2(9)：772-774.
[29]颜永进,李明春,浦大玲,等.葛根素对心肌缺血再灌注损伤保护作用的研究[J].南通大学学报(医学版)2005；25(6)：407-409.
[30]吴青,周祖玉,陶大昌.葛根素预处理对大鼠缺血再灌注心肌细胞凋亡的影响[J].基础医学与临床2005；25(2)：147-151.
[31]夏鑫华,刘梅,张志敏,等.丹参中水溶性成分体外抗氧化活性研究[J].中华中医药学刊2009；27(5)：1085-1087.
[32]李琳,孙莉莎,徐江平.丹酚酸B对犬心肌梗死的治疗作用[J].中成药2004,26(3)：215-218.
[33]黄凯文,祝维峰,苏宁,等.丹参酮ⅡA和丹酚酸B抗心脑缺血的比较研究[J].中国医院用药评价与分析2009,9(6)：449-45.
[34]叶挺祥.丹酚酸B对血管内皮细胞NO合成的影响[D].天津大学硕士学位论文.2006.
[35]柴丽娟,张萌,王虹,等.SaIB/PNS配伍对心肌梗死后炎症因子表达的影响[J].河南中医2008,28(8)：28-30.
[36]张发艳,华声瑜,范英昌.丹酚酸B及丹参酮ⅡA对家兔动脉粥样硬化IL-8及VCAM-1的影响[J].山东中医药大学学报2006,30(2)：152-154.
[37]豆利华.丹参酮ⅡA磺酸钠在体外循环心脏直视术中缺血早期心肌保护作用及对IMA、GPBB水平的影响[J].河北医药2010；32(17)：2327-2329.
[38]王丽娟,王勇,邱丽萍,等.灯盏花素对豚鼠单一心室肌细胞ICa的抑制作用[J].中国现代应用药学杂志2000；17(4)：272-274.
[39]毛孙忠,严哲,谢于鹏.灯盏花注射液对大鼠慢性低氧性心肌损伤的预防作用[J].中西医结合学报2004；2(2)：117-119.
[40]袁红霞,陈艳春.黄芪的现代药理研究及其临床应用[J].山东中医药大学学报2000；24(5)：397-400.
[41]韩光辉.大剂量黄芪注射液治疗冠心病88例[J].河南医科大学学报1999；34(4)：85.
[42]李荣.黄芪注射液治疗缺血性心脏病临床分析[J].中国现代医生2009；47(19)：152-159.
[43]江伟芬,丁律中.参麦和黄芪注射液治疗慢性肺源性心脏病心力衰竭38例疗效观察[J].中国中西医结合急救杂志2007；14(6)：378-379.
[44]逯艳梅,曹甦.黄芪注射液治疗小儿病毒性心肌炎疗效观察[J].现代中西医结合杂志2010；19(2)：181-182.
[45]章庆红.丹红注射液临床应用研究[J].河北医药2010；32(20)：2909-2911.
[46]费松柏,管耘园,张莉,等.丹红注射液联合阿托伐他汀对急性冠脉综合征患者IL-6、sCD40L和APN的影响[J].中西医结合心脑血管病杂志2010；8(9)：1035-1037.
[47]Liang Hong. Danhong injection effects on vascular endothelial function in patients undergoing coronary artery stent implantation[J]. J Clinical Rehabilitative Tissue Engineering Research中国组织工程研究与临床康复)2010；14(13)：2467-2470.
[48]管耘园,费松柏,王毅,等.丹红注射液对急性冠脉综合征患者炎症因子及血栓素B2的影响[J].中西医结合心脑血管病杂志2010；8(9)：1039-1040.
[49]刘志远,张中华,李国龙,等.丹红注射液对不稳定型心绞痛患者血浆一氧化氮及c反应蛋白的影响[J].山西医药2010；39(3)：197-198.
[50]陈雪斌,马利平,翟丽莉.丹红注射液治疗缺血性心肌病心力衰竭的临床研究[J].实用心脑肺血管病杂志2008；16(12)：31-32.
[51]顾家珍,李俊,刘世清,等.心内直视手术中复方丹参的心肌保护作用[J].中国中西医结合杂志1998；18(2)：68-70.
[52]李国虎,陈胜喜,许疗梅,等.生脉心停搏液对体外循环开心手术病人的心肌保护作用[J].湖南医科大学学报1998,23(3)：305-308.
[53]侯智亮.生脉注射液对心脏手术心肌保护作用的临床观察[J].中国现代医生2010；48(1)：51-52.
[1]Boheler KR, Czyz J, Tweedie D, et al. Differentiation of pluripotent embryonic stem cells into cardiomyocytes.[J] Circ Res,2002; 91(3):189-201.
[2]尹青,赵昱,赵秀军,等.5-氮胞苷诱导体外培养的胚胎干细胞向心肌细胞分化.[J]基础医学与临床,2007；27(5)：549-552.
[3]HeschelerJ, Fleischmann BK, Lentini S, et al. Embryonic stem cells:a model to study structural and functional properties in cardiomyogenesis.[J] Cardiovasc Res,1997; 36 (2):149-162.
[4]Sachinidis A,Fleischmann BK, Kolossov E,et al. Cardiac specific differentiation of mouse embryonic stem cells.[J] Cardiovasc Res,2003; 8 (2):278-291.
[5]Zhu DY, Qu LH, Zhang XN,et al. Icariin-mediated modulation of cell cycle and p53 during cardiomyocyte differentiation in embryonic stem cells.[J] Eur J Pharmacol,2005;514(2-3):99-110.
[6]Zhu DY, Lou YJ. Inducible effects of icariin, icaritin, and desmethylicaritin on directional differentiation of embryonic stem cells into cardiomyocytes in vitro.[J] Acta Pharmacologica Sinica,2005; 26 (4):477-485.
[7]Ding L, Liang XG, Hu Y. Involvement of p38MAPK and reactive oxygen species in icariin-induced cardiomyocyte differentiation of murine embryonic stem cells in vitro.[J] Stem Cells Dev,2008; 17(4): 751-760.
[8]王芳洁,易岂建,郭鹏飞.小鼠胚胎干细胞分化为心肌细胞的体外实验.[J]第四军医大学学报,2009；39(9)：808-811.
[9]马晓辉,高长青,李伯君,等.骨髓间充质干细胞移植治疗急性心肌梗死的实验研究.[J]中华医学杂志,2009；89(15)：1067-1070.
[10]Hare JM, Traverse JH, Henry TD, et al. A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Intravenous Adult Human Mesenchymal Stem Cells (Prochymal) After Acute Myocardial Infarction.[J] Am Coll Cardiol,2009;54(24):2277-2286.
[11]汪朝晖,冼绍祥,杨忠奇,等.人参总皂苷诱导骨髓间充质干细胞分化为心肌细胞的实验研究.[J]广州中医药大学学报,2006；23(2)：100-103.
[12]杨忠奇,冼绍祥,汪朝晖,等.三七总皂苷对骨髓间充质干细胞分化为心肌样细胞的作用.[J]中药新药与临床药理,2006；17(4)：239-242.
[13]冼绍祥,杨忠奇,汪朝晖,等.黄芪甲苷体外诱导骨髓间充质干细胞分化为心肌样细胞的实验研究.[J]广州中医药大学学报,2007；24(1)：37-40.
[14]杨庆有,冼绍祥,孙慧茹,等.黄芪含药血清诱导骨髓间充质干细胞分化为心肌样细胞的实验研究.[J]辽宁中医杂志,2008；35(6)：832-834.
[15]谢玲玲.淫羊藿苷诱导骨髓间充质干细胞分化心肌样细胞的实验研究[D].广州：广州中医药大学中西医结合基础专业,2008.
[16]刘韶英.淫羊藿苷对骨髓间充质干细胞增殖及向心肌细胞分化的影响[D].北京：北京中医药大学中西医结合临床专业,2008.
[17]Leri A, Kajstura J, Anversa P. Cardiac stem cells and mechanisms of myocardial regeneration.[J] Physiol Rev, 2005; 85(4):1373-1416.
[18]Itzhaki-Alfia A, Leor J, Raanani E, et al. Patient characteristics and cell source determine the number of isolated human cardiac progenitor cells.[J] Circulation,2009; 120(25):2559-2566.
[19]Smits AM, van Vliet P, Metz CH, et al. Human cardiomyocyte progenitor cells differentiate into functional mature cardiomyocytes:an in vitro model for studying human cardiac physiology and pathophysiology.[J] Nat Protoc,2009; 4(2):232-243.
[20]魏强,赵强,魏来,等.成人心肌干细胞的体外培养纯化与鉴定.[J]中国临床医学,2009；16(2)：187-190.
[21]陆东风,吴昊,黄璟,等.新生SD大鼠心肌干细胞的体外分离培养与鉴定.[J]南方医科大学学报,2006；26(11)：1629-1632.
[22]姜宏,施广飞.心肌干细胞培养和纯化的实验方法研究.[J]现代生物医学进展,2009；9(1)：33-35.
[23]姜宏,施广飞.5-氮胞苷诱导心肌组织中c-kit+干细胞分化的实验研究.[J]中国临床药理学与治疗学,2008；13(9)：996-1001.
[24]Tomita Y, Makino S, Hakuno D, et al. Application of mesenchymalstem cell-derived cardiomyocytes as bio-pacemakers:current s tatus and problems to be solved.[J] Med Biol Eng Comput,2007;45(2):209-220.
[2]Braunwald E, Kloner RA. Myocardial reperfusion:a double-edged sword?[J] J Clin Invest 1985;76(5): 1713-1719.
[3]Yellon DM, Baxter GF. Protecting the ischaemic and reperfused myocardium in acute myocardial infarction:distant dream or near reality?[J] Heart 2000;83(4):381-387.
[4]Lazzarino G, Raatikainen P, Nuutinen M, et al. Myocardial release of malondialdehyde and purine compounds during coronary bypass surgery.[J] Circulation 1994;90(1):291-297.
[5]Piper HM, Meuter K, Schafer C. Cellular mechanisms of ischemia-reperfusion injury.[J]Ann Thorac Surg 2003;75(2):S644-S648.
[6]Gross GJ,Kersten JR,Warltier DC. Mechanisms of postischemic contractile dysfunction.[J]Ann Thorac Surg 1999;68(5):1898-1904.
[7]Neves LA, Almeida AP, Khosla MC, et al. Effect of angiotensin-(1-7)on reperfusion arrhythmias in isolated rat hearts.[J] Braz J Med Biol Res 1997;30(6):801-809.
[8]Kloner RA, Giacomelli F, Alker KJ, et al. Influx of neutrophils into the walls of large epicardial coronary arteries in response to ischemia/reperfusion.[J] Circulation 1991;84(4):1758-1772.
[9]Xiao CY, Hara A, Yuhki K, et al. Roles ofprostaglandin I(2)and thromboxane A(2)in cardiac ischemia-reperfusion injury:a study using mice lacking their respective receptors.[J]Circulation 2001;104(18): 2210-2215.
[10]Heyndrickx GR, Millard RW, McRitchie RJ, et al. Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs.[J] J Clin Invest 1975;56(4):978-985.
[11]Kloner RA, Arimie RB, Kay GL, et al. Evidence for stunned myocardium in humans:a 2001 update.[J] Coron Artery Dis 2001;12(5):349-356.
[12]Manning AS, Hearse DJ. Reperfusion-induced arrhythmias:mechanisms and prevention.[J] J Mol Cell Cardiol 1984; 16(6):497-518.
[13]Meerson FZ, Belkina LM, Sazontova TG, et al. The role of lipid peroxidation in pathogenesis of arrhythmias and prevention of cardiac fibrillation with antioxidants.[J] Basic Res Cardiol 1987;82(2):123-137.
[14]Piper HM, Meuter K, Schafer C. Cellular mechanisms of ischemia-reperfusion injury.[J] Ann Thorac Surg 2003;75(2):S644-S648.
[15]Ku DD. Coronary vascular reactivity after acute myocardial ischemia.[J] Science 1982;218(4572): 576-578.
[16]Lefer AM, Lefer DJ. The role of nitric oxide and cell adhesion molecules on the microcirculation in ischaemia-reperfusion.[J] Cardiovasc Res 1996;32(4):743-751.
[17]Canbaz S, Duran E, Ege T, et al. The effects of intracoronary administration of vitamin E on myocardial ischemia-reperfusion injury during coronary artery surgery.[J] Thorac Cardiovasc Surg 2003;51(2):57-61.
[18]Li XS, Uriuda Y, Wang QD, et al. Role of 1-arginine in preventing myocardial and endothelial injury following ischaemia/reperfusion in the rat isolated heart.[J] Acta Physiol Scand 1996; 156(1):37-44.
[19]Lerman A, Burnett Jr JC, Higano ST, et al. Long-term 1-arginine supplementation improves small-vessel coronary endothelial function in humans.[J] Circulation 1998;97(21):2123-2128.
[20]Rodriguez-Sinovas A, Garcia-Dorado D, Padilla F, et al. Pre-treatment with the Na+/H+exchange inhibitor cariporide delays cell-to-cell electrical uncoupling during myocardial ischemia.[J] Cardiovasc Res 2003;58(l): 109-117.
[21]Garcia-Dorado D, Theroux P, Duran JM, et al. Selective inhibition of the contractile apparatus.A new approach to modification of infarct size, infarct composition, and infarct geometry during coronary artery occlusion and reperfusion.[J] Circulation 1992;85(3):1160-1174.
[22]李勤,刘宏.生脉注射液的药理作用及临床应用.[J]医学综述2005；11(10)：950-951.
[23]蒙定水,孙素红,甘照儒,等.生脉注射液对心肺复苏兔心肌细胞的作用及应用时机的研究.[J]广西中医药2005；28(4)：45-47.
[24]尹旭斌.生脉合复方丹参注射液治疗急性病毒性心肌炎40例.[J]中国中医急症2002；11(5)：380.
[25]张西联,黄跃生,党永明,等.生脉注射液对大鼠烧伤后心肌细胞凋亡的影响.[J]第三军医大学学报2007；29(2)：94-96.
[26]张亚臣,陈捷,吕宝经,等.生脉注射液对肥厚心肌超微结构和钙泵功能的影响.[J]上海第二医科大学学报2005；25(10)：1022-1024.
[27]吕宝经,张亚臣,郑宏超,等.左室造影评价生脉注射液改善冠心病患者心功能的作用.[J]中国临床药学杂志2005,14(4)：207-209.
[28]党波,商惠萍,江丽.生脉注射液对冠心病患者内皮功能的影响.[J]陕西中医2005；26(7)：639-640.
[29]侯智亮.生脉注射液对心脏手术心肌保护作用的临床观察.[J]中国现代医生2010；48(1)：51-52.
[30]何涛,张红星,高清元.生脉注射液在心脏直视手术中对心肌缺血再灌注损伤的保护作用.[J]临床医药实践2005；14(1)：28-29.
[31]Leri A, Kajstura J, Anversa P. Cardiac stem cells and mechanisms of myocardial regeneration.[J] Physiol Rev 2005; 85(4):1373-1416.
[32]Itzhaki-Alfia A, Leor J, Raanani E, et al. Patient characteristics and cell source determine the number of isolated human cardiac progenitor cells.[J] Circulation 2009; 120(25):2559-2566.
[33]Smits AM, van Vliet P, Metz CH, et al. Human cardiomyocyte progenitor cells differentiate into functional mature cardiomyocytes:an in vitro model for studying human cardiac physiology and pathophysiology.[J] Nat Protoc 2009; 4(2):232-43.
[34]姜宏,施广飞.心肌干细胞培养和纯化的实验方法研究.[J]现代生物医学进展2009；9(1)：33-35.
[35]姜宏,施广飞.5-氮胞苷诱导心肌组织中c-kit+干细胞分化的实验研究.[J]中国临床药理学与治疗学2008；13(9)：996-1001.
[36]Tomita Y, Makino S, Hakuno D, et al. Application of mesenchymalstem cell-derived cardiomyocytes as bio-pacemakers:current s tatus and problems to be solved.[J] Med Biol Eng Comput 2007;45(2):209-220.
[1]Leri A, Kajstura J, Anversa P. Cardiac stem cells and mechanisms of myocardial regeneration.[J] Physiol Rev,2005; 85(4):1373-416.
[2]Itzhaki-Alfia A, Leor J, Raanani E, et al. Patient characteristics and cell source determine the number of isolated human cardiac progenitor cells.[J] Circulation,2009; 120(25):2559-66.
[3]Smits AM, van Vliet P, Metz CH, et al. Human cardiomyocyte progenitor cells differentiate into functional mature cardiomyocytes:an in vitro model for studying human cardiac physiology and pathophysiology.[J] Nat Protoc,2009; 4(2):232-43.
[4]Leri A, Kajstura J, Anversa P. Cardiac stem cells and mechanisms of myocardial regeneration.[J] Physiol Rev,2005; 85(4):1373-416.
[5]Holmes C, Stanford WL. Concise review:stem cell antigen-1:expression, function, and enigma.[J] Stem Cells,2007; 25(6):1339-47.
[6]Urbanek K, Torella D, Sheikh F, et al. Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure.[J] Proc Natl Acad Sci USA,2005; 102(24):8692-8697.
[7]汪朝晖,冼绍祥,杨忠奇,等.人参总皂苷诱导骨髓间充质干细胞分化为心肌细胞的实验研究.[J]广州中医药大学学报,2006；23(2)：100-103.
[8]杨忠奇,冼绍祥,汪朝晖,等.三七总皂苷对骨髓间充质干细胞分化为心肌样细胞的作用.[J]中药新药与临床药理,2006；17(4)：239-242。
[9]冼绍祥,杨忠奇,汪朝晖,等.黄芪甲苷体外诱导骨髓间充质干细胞分化为心肌样细胞的实验研究.[J]广州中医药大学学报,2007；24(1)：37-40.
[10]杨庆有,冼绍祥,孙慧茹,等.黄芪含药血清诱导骨髓间充质干细胞分化为心肌样细胞的实验研究.[J]辽宁中医杂志,2008；35(6)：832-834.
[11]谢玲玲.淫羊藿苷诱导骨髓间充质干细胞分化心肌样细胞的实验研究.[D]广州：广州中医药大学中西医结合基础专业,2008.
[12]罗明凤,张三印,黄秀深,等.参附注射液和生脉注射液对心肌细胞Ca2+-ATP酶影响的对比研究.[J]天津中医药,2008；25(6)：487-490.
[13]陈海霞,王晓春,张阳德,等.生脉注射液对人骨髓造血细胞增殖作用的研究.[J]中国实用内科杂志,2006；26(2)：118-120.
[1]Yellon DM,Baxter GF. Protecting the ischaemic and reperfused myocardium in acute myocardial infarction:distant dream or near reality?[J] Heart 2000;83(4):381-387.
[2]Nicolini F, Beghi C, Muscari C, et al. Myocardial protection in adult cardiac surgery:current options and future challenges.[J] Eur J Cardiothorac Surg 2003; 24(6):986-993.
[3]豆利华.丹参酮ⅡA磺酸钠在体外循环心脏直视术中缺血早期心肌保护作用及对IMA、GPBB水平的影响.[J]河北医药2010；32(17)：2327-2329.
[4]顾家珍,李俊,刘世清,等.心内直视手术中复方丹参的心肌保护作用.[J]中国中西医结合杂志1998；18(2)：68-70.
[5]侯智亮.生脉注射液对心脏手术心肌保护作用的临床观察.[J]中国现代医生2010；48(1)：51-52.
[6]吕民,姜亦忠,张秀和,等.生脉注射液对心肌缺血与再灌注损伤的保护作用.[J]吉林大学学报(医学版)2005；31(3)：446-448.
[7]Cohn LH."Fifty years of open-heart surgery".[J] Circulation 2003;107(17):2168-2170.
[8]Braunwald E,Kloner RA.Myocardial reperfusion:a double-edged sword?.[J] J Clin Invest 1985;76(5):1713-1719.
[9]Jennings RB, Sommers HM, Smyth GA, et al. Myocardial necrosis induced by temporary occlusion of a coronaryartery in the dog.[J] Arch Pathol 1960;70:68-78.
[10]Bulkley BH. Myocardial consequences of coronary artery bypass graft surgery:the paradox of necrosis in areas of revascularization.[J] Circulation 1977;56(6):906-913.
[11]Lazzarino G, Raatikainen P, Nuutinen M, et al. Myocardial release of malondialdehyde and purine compounds during coronary bypass surgery.[J] Circulation 1994;90(1):291-297.
[12]Piper HM, Meuter K, Schafer C. Cellular mechanisms of ischemia-reperfusion injury.[J]Ann Thorac Surg 2003;75(2):S644-S648.
[13]Gross GJ,Kersten JR,Warltier DC. Mechanisms of postischemic contractile dysfunction.[J]Ann Thorac Surg 1999;68(5):1898-1904.
[14]Neves LA, Almeida AP, Khosla MC, et al. Effect of angiotensin-(1-7)on reperfusion arrhythmias in isolated rat hearts.[J] Braz J Med Biol Res 1997;30(6):801-809.
[15]Kloner RA, Giacomelli F, Alker KJ, et al. Influx of neutrophils into the walls of large epicardial coronary arteries in response to ischemia/reperfusion.[J] Circulation 1991;84(4):1758-1772.
[16]Xiao CY, Hara A, Yuhki K, et al. Roles ofprostaglandin I(2)and thromboxane A(2)in cardiac ischemia-reperfusion injury:a study using mice lacking their respective receptors.[J] Circulation 2001;104(18): 2210-2215.
[17]Canbaz S, Duran E, Ege T, et al. The effects of intracoronary administration of vitamin E on myocardial ischemia-reperfusion injury during coronary artery surgery.[J] Thorac Cardiovasc Surg 2003;51(2):57-61.
[18]Li XS, Uriuda Y, Wang QD, et al. Role of 1-arginine in preventing myocardial and endothelial injury following ischaemia/reperfusion in the rat isolated heart.[J] Acta Physiol Scand 1996;156(1):37-44.
[19]Lerman A, Burnett Jr JC, Higano ST, et al. Long-term 1-arginine supplementation improves small-vessel coronary endothelial function in humans.[J] Circulation 1998;97(21):2123-2128.
[20]Rodriguez-Sinovas A, Garcia-Dorado D, Padilla F, et al. Pre-treatment with the Na+/H+exchange inhibitor cariporide delays cell-to-cell electrical uncoupling during myocardial ischemia.[J] Cardiovasc Res 2003;58(l): 109-117.
[21]Garcia-Dorado D, Theroux P, Duran JM, et al. Selective inhibition of the contractile apparatus.A new approach to modification of infarct size, infarct composition, and infarct geometry during coronary artery occlusion and reperfusion.[J] Circulation 1992;85(3):1160-1174.
[22]Maruyama M, Farber NE, Vercellotti GM, et al. Evidence for a role of platelet activating factor in the pathogenesis of irreversible but not reversible myocardial injury after reperfusion in dogs[J]. Am Heart J 1990;120(3):510-520.
[23]Vermeiren GL, Claeys MJ, Van Bockstaele D, et al. Reperfusion injury after focal myocardial ischemia:polymorphonuclear leukocyte activation and its clinical implications[J]. Resuscitation 2000;45(l): 35-61.
[24]周迎春,陈镜合.心肌细胞保护作用的中药研究进展[J].中医药信息2000；17(6)：26-28.
[25]李国虎,陈胜喜,许疗梅,等.生脉心停搏液对体外循环开心手术病人的心肌保护作用[J].湖南医科大学学报1998,23(3)：305-308.
[26]侯智亮.生脉注射液对心脏手术心肌保护作用的临床观察[J].中国现代医生2010；48(1)：51-52.
[27]Lints TJ, Parsons LM, Hartley L, et al. Nkx-2.5:a novel murine homeobox gene expressed in early heart progenitor cells and their myogenic descendants.[J] Development 1993; 119(2):419-431.
[28]Molkentin JD.The zinc finger-containing transcription factors GATA-4,-5, and-6. Ubiquitously expressed regulators of tissue-specific gene expression. J Biol Chem 2000;275(50):38949-38952.
[29]Peterkin T, Gibson A, Loose M, et al. The roles of GATA-4,-5 and-6 in vertebrate heart development. Semin Cell Dev Biol 2005;16(1):83-94.
[30]Davidson SM, Morange M. Hsp25 and the p38 MAPK pathway are involved in differentiation of cardiomyocytes. Dev Biol 2000;218(2):146-160.
[31]Raffin M, Leong LM, Rones MS, et al. Subdivision of the cardiac Nkx2.5 expression domain into myogenic and nonmyogenic compartments. Dev Biol 2000;218(2):326-40.
[32]Panteghini M. Present issues in the determination of troponins and other markers of cardiac damage. Clin Biochem 2000;33(3):161-166.
[33]Moscoso I, centrno A, lopez E, et al.Differentiation "in vitro" of primary and immortalized porcine mesenchymal stem cells into cardiomyocytes for cell transplantation. Transplant Proc 2005;37(1):481-482.
[34]Toyofuku T, Yabubi M, Otsu K, et al. Intercellular calcium signaling via gap junction in connexin-43 transfected cells. J Bio Chem 1998;273(3):1519-1528.
[35]Tomit AS, Schuesslar RB, Berul CI, et al. Disparate effects of deficient expression of connexin-43 on atrial and ventricular conduction. Circulation 1998;97(7):686-691.
[1]秦小奎,刘晓方.113例主动脉夹层的危险因素报告及文献综合分析[J].中华心血管病杂志,2006；34(6)：527-529.
[2]张源明,陈曦,木胡牙提,等.乌鲁木齐市主动脉夹层病例临床特征变化趋势10年回顾性分析[J].中华流行病学杂志,2008；29(7)：720-723.
[3]曾红科,方明,孙诚,等.主动脉夹层累及范围与患者症状关系的临床分析[J].中华心血管病杂志,2004；32(6)：516-518.
[4]薛凌,罗建方,黄文晖,等.主动脉夹层患者临床特征的性别差异[J].中华心血管病杂志,2008；36(5)：415-417.
[5]张源明,周立英,何秉贤,等.主动脉夹层106例的临床分析[J].中华心血管病杂志,2005；33(6)：536-538.
[6]明广华,张宇辉,吴海英,等.179例主动脉夹层患者的临床分析[J].中国循环杂志,2004；19(5)：363-366.
[7]薛凌,罗建方,麦劲壮,等.广州市主动脉夹层临床特征变化趋势十年回顾性分析[J].中华心血管病杂志,2007；35(1)：47-50.
[8]徐冬梅,范崇伦,张梅,等.主动脉夹层106例临床分析[J].山东医药,2003；43(10)：32-33.
[9]周建华,李连镇.主动脉夹层116例临床分析[J].首都医药,2004；18：17-18.
[10]罗勇,王春生,丁文军.38例急性主动脉夹层的临床分析[J].四川大学学报(医学版),2004；35(4)： 589-590.
[11]宋玉娥,王琳,马业新,等.主动脉夹层90例临床分析[J].内科急危重杂志,2004；10(2)：69-71.
[12]Hagan PG, Nienaber CA, Isselbacher EM, et al. The International Registry of Acute Aortic Dissection (IRAD):new insights into an old disease[J]. JAMA,2000; 283(7):897-903.
[13]Golledge J, Eagle KA. Acute aortic dissection[J]. Lancet,2008; 372(9632):55-66.
[14]Collins JS, Evangelista A, Nienaber CA, et al. International Registry of Acute Aortic Dissection (IRAD). Differences in clinical presentation, management, and outcomes of acute type a aortic dissection in patients with and without previous cardiac surgery[J]. Circulation,2004; 110(suppl 1):II237-II242.
[15]Suzuki T, Mehta RH, Ince H, et al. International Registry of Aortic Dissection (IRAD). Clinical profi les and outcomes of acute type B aortic dissection in the current era:lessons from the International Registry of Aortic Dissection (IRAD) [J]. Circulation,2003; 108 (suppl 1):11312-11317.
[16]Tsai TT, Isselbacher EM, Trimarchi S, et al. Acute type B aortic dissection:does aortic arch involvement affect management and outcomes? Insights from the International Registry of Acute Aortic Dissection (IRAD) [J]. Circulation,2007; 116(11 Suppl):1150-1156.
[17]Hirst Jr AE, Johns Jr VJ, Kime Jr SW. Dissecting aneurysm of the aorta:a review of 505 cases[J]. Medicine (Baltimore),1958;37:217-279.
[18]赵秀丽,陈捷,崔艳丽,等.中国14省市高血压现状的流行病学研究[J].中华医学杂志,2006；86(16)：1148-1152.
[19]Centers for Disease Control and Prevention (CDC). Racial/ethnic disparities in p revalence, treatment, and control of hypertension-United States,1999-2002[R]. MMWR Morb MortalWkly Rep,2005;54:7-9.
[20]Yu HY, Chen YS, Huang SC, et al. Late outcome of patients with aortic dissection:study of a national database[J]. Eur J Cardiothorac Surg,2004;25(5):683-690.
[21]Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension:analysis of worldwide data[J]. Lancet,2005;365(9455):217-223.
[22]马冠生,孔灵芝,栾德春,等.中国居民吸烟行为的现状分析[J].中国慢性病预防与控制2005；13(5)：195-199.
[23]Judith M, Michael E. The tobacco control atlas[R]. Geneva:WHO,2002:25-27.
[24]Charbonneau NL, Ono RN, Corson GM, et al. Fine tuning of growth factor signals depends on fibrillin microfibril networks[J]. Birth Defects Res C Embryo Today,2004;72(1):37-50.
[25]Alva JA, Iruela-Arispe ML. Notch signaling in vascular morphogenesis[J]. Curr Opin Hematol,2004; 11(4):278-283.
[26]Cohn LH. Cardiac surgery in the adult.3th Edition[M]. New York:The McGraw-Hill Companies, Inc, 2007.1195-1222.
[27]Tsai TT, Trimarchi S, Nienaber CA. Acute aortic dissection:perspectives from the International Registry of Acute Aortic Dissection (IRAD) [J]. Eur J Vase Endovasc Surg,2009;37(2):149-159.
[28]Angouras D, Sokolis DP, Dosios T, et al. Effect of impaired vasa vasorum flow on the structure and mechanics of the thoracic aorta:implications for the pathogenesis of aortic dissection[J]. Eur J Cardiothorac Surg,2000; 17(4):468-474.
[1]Yellon DM, Baxter GF. Protecting the ischaemic and reperfused myocardium in acute myocardial infarction:distant dream or near reality?[J]. Heart 2000;83(4):381-387.
[2]Nicolini F, Beghi C, Muscari C, et al. Myocardial protection in adult cardiac surgery:current options and future challenges[J]. Eur J Cardiothorac Surg 2003;24(6):986-993.
[3]Jennings RB, Sommers HM, Smyth GA, et al. Myocardial necrosis induced by temporary occlusion of a coronaryartery in the dog[J]. Arch Pathol 1960;70:68-78.
[4]Bulkley BH. Myocardial consequences of coronary artery bypass graft surgery:the paradox of necrosis in areas of revascularization[J]. Circulation 1977;56(6):906-913.
[5]MoensAL,Claeys MJ,Timmermans JP,et al.Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process[J]. Int J Cardiol 2005;100(2):179-190.
[6]Fremes SE, Weisel RD, Mickle DAG, et al. Myocardial metabolism and ventricular function following cold potassium cardioplegia[J]. J Thorac Cardiovasc Surg 1985;89(4):531-546.
[7]Teoh KH, Christakis GT, Weisel RD, et al. Accelerated myocardial metabolic recovery with terminal warm blood cardioplegia(hot shot)[J]. J Thorac Cardiovasc Surg 1986;91(6):888-895.
[8]Ikonomidis JS, Rao V, Weisel RD, et al. Myocardial protection for coronary bypass grafting:The Toronto Hospital perspective[J]. Ann Thorac Surg 1995;60(3):824-832.
[9]Calafiore AM, Teodori G, Mezzetti, et al. Intermittent antegrade warm blood cardioplegia[J]. Ann Thorac Surg 1995;59(2):398-402.
[10]Maruyama M, Farber NE, Vercellotti GM, et al. Evidence for a role of platelet activating factor in the pathogenesis of irreversible but not reversible myocardial injury after reperfusion in dogs[J]. Am Heart J 1990;120(3):510-520.
[11]Vermeiren GL, Claeys MJ, Van Bockstaele D, et al. Reperfusion injury after focal myocardial ischemia:polymorphonuclear leukocyte activation and its clinical implications[J]. Resuscitation 2000;45(l): 35-61.
[12]Ghosh S, Standen NB, Galinanes M. Preconditioning the humanmyocardium by simulated ischemia: studies on the early and delayed protection [J]. Cardiovasc Res 2000;45(2):339-350.
[13]Yellon DM, Baxter GF. Sodium-hydrogen exchange in myocardial reperfusion injury[J]. Lancet 2000;356(9229):522-523.
[14]周迎春,陈镜合.心肌细胞保护作用的中药研究进展[J].中医药信息2000；17(6)：26-28.
[15]Fu GC, Zhang JF, Li YQ., et al. Effects of Sodium ferulate during heart ischemic reperfusion injury in isolate rats[J]. J Henan Med Univ(河南医科大学学报) 1994;29(4):344-346.
[16]洪立明.阿魏酸钠抗实验性心律失常的作用[J].中国药理学通报2002；18(3)：323-325.
[17]句海松,李小洁.阿魏酸钠和18β-苷草次酸对氧自由基的清除作用[J].中国药理学报1999；11(5)：466-470.
[18]谢可鸣,茆勇.阿魏酸钠对小鼠炎性肝损伤的抑制效应及其与ICAM-1和E-selection表达的关系研究[J].中国病理生理杂志2004；20(12)：2330-2335.
[19]傅颖君,何明.阿魏酸钠与心肌保护[J].江西医学院学报2005；45(5)：177-179.
[20]Murry CE, Jennings RB, Peimer KA. Proconditioning withis-chemia:a delay of lethalcell injury in ischemic myocardium[J]. Circulation 1986;74(5):1124-1136.
[21]傅颖君,何明.阿魏酸钠对心肌细胞缺氧/复氧损伤的保护作用及其机制[J].药学学报2004；39(5)：325-327.
[22]刘季春,万力,高涛,等.阿魏酸钠对心内直视手术的心肌保护作用[J].江西医学院学报2007；47(4)：20-25.
[23]高伟,梁日欣,肖永庆等.川芎内酯A预处理对心肌微血管内皮细胞缺氧/复氧损伤保护作用及机制研究[J].中国中药杂志2007；32(2)：133-137.
[24]程伟,易慧智.川芎嗪对大鼠缺血再灌注心肌细胞凋亡的影响[J].中国中医基础医学杂志2007；13(6)：449-450.
[25]陈江斌,唐其柱,孙小梅,等.川芎嗪对复氧后损伤心肌细胞的影响[J].中国现代应用药学2001；18(3)：190-191.
[26]古小明,何明.川芎嗪预处理对心肌细胞缺血/再灌注损伤延迟保护作用[J].广东药学院学报2007；23(2)：183-185.
[27]孙鹏,刘金龙.葛根素对组织缺血再灌注损伤保护机制的研究进展[J].现代中西医结合杂志2006；15(3)：405-407.
[28]吴青,陶宏凯,陶大昌.葛根素对大鼠缺血再灌注心肌细胞保护作用的研究[J].中华现代中西医杂志2004；2(9)：772-774.
[29]颜永进,李明春,浦大玲,等.葛根素对心肌缺血再灌注损伤保护作用的研究[J].南通大学学报(医学版)2005；25(6)：407-409.
[30]吴青,周祖玉,陶大昌.葛根素预处理对大鼠缺血再灌注心肌细胞凋亡的影响[J].基础医学与临床2005；25(2)：147-151.
[31]夏鑫华,刘梅,张志敏,等.丹参中水溶性成分体外抗氧化活性研究[J].中华中医药学刊2009；27(5)：1085-1087.
[32]李琳,孙莉莎,徐江平.丹酚酸B对犬心肌梗死的治疗作用[J].中成药2004,26(3)：215-218.
[33]黄凯文,祝维峰,苏宁,等.丹参酮ⅡA和丹酚酸B抗心脑缺血的比较研究[J].中国医院用药评价与分析2009,9(6)：449-45.
[34]叶挺祥.丹酚酸B对血管内皮细胞NO合成的影响[D].天津大学硕士学位论文.2006.
[35]柴丽娟,张萌,王虹,等.SaIB/PNS配伍对心肌梗死后炎症因子表达的影响[J].河南中医2008,28(8)：28-30.
[36]张发艳,华声瑜,范英昌.丹酚酸B及丹参酮ⅡA对家兔动脉粥样硬化IL-8及VCAM-1的影响[J].山东中医药大学学报2006,30(2)：152-154.
[37]豆利华.丹参酮ⅡA磺酸钠在体外循环心脏直视术中缺血早期心肌保护作用及对IMA、GPBB水平的影响[J].河北医药2010；32(17)：2327-2329.
[38]王丽娟,王勇,邱丽萍,等.灯盏花素对豚鼠单一心室肌细胞ICa的抑制作用[J].中国现代应用药学杂志2000；17(4)：272-274.
[39]毛孙忠,严哲,谢于鹏.灯盏花注射液对大鼠慢性低氧性心肌损伤的预防作用[J].中西医结合学报2004；2(2)：117-119.
[40]袁红霞,陈艳春.黄芪的现代药理研究及其临床应用[J].山东中医药大学学报2000；24(5)：397-400.
[41]韩光辉.大剂量黄芪注射液治疗冠心病88例[J].河南医科大学学报1999；34(4)：85.
[42]李荣.黄芪注射液治疗缺血性心脏病临床分析[J].中国现代医生2009；47(19)：152-159.
[43]江伟芬,丁律中.参麦和黄芪注射液治疗慢性肺源性心脏病心力衰竭38例疗效观察[J].中国中西医结合急救杂志2007；14(6)：378-379.
[44]逯艳梅,曹甦.黄芪注射液治疗小儿病毒性心肌炎疗效观察[J].现代中西医结合杂志2010；19(2)：181-182.
[45]章庆红.丹红注射液临床应用研究[J].河北医药2010；32(20)：2909-2911.
[46]费松柏,管耘园,张莉,等.丹红注射液联合阿托伐他汀对急性冠脉综合征患者IL-6、sCD40L和APN的影响[J].中西医结合心脑血管病杂志2010；8(9)：1035-1037.
[47]Liang Hong. Danhong injection effects on vascular endothelial function in patients undergoing coronary artery stent implantation[J]. J Clinical Rehabilitative Tissue Engineering Research中国组织工程研究与临床康复)2010；14(13)：2467-2470.
[48]管耘园,费松柏,王毅,等.丹红注射液对急性冠脉综合征患者炎症因子及血栓素B2的影响[J].中西医结合心脑血管病杂志2010；8(9)：1039-1040.
[49]刘志远,张中华,李国龙,等.丹红注射液对不稳定型心绞痛患者血浆一氧化氮及c反应蛋白的影响[J].山西医药2010；39(3)：197-198.
[50]陈雪斌,马利平,翟丽莉.丹红注射液治疗缺血性心肌病心力衰竭的临床研究[J].实用心脑肺血管病杂志2008；16(12)：31-32.
[51]顾家珍,李俊,刘世清,等.心内直视手术中复方丹参的心肌保护作用[J].中国中西医结合杂志1998；18(2)：68-70.
[52]李国虎,陈胜喜,许疗梅,等.生脉心停搏液对体外循环开心手术病人的心肌保护作用[J].湖南医科大学学报1998,23(3)：305-308.
[53]侯智亮.生脉注射液对心脏手术心肌保护作用的临床观察[J].中国现代医生2010；48(1)：51-52.
[1]Boheler KR, Czyz J, Tweedie D, et al. Differentiation of pluripotent embryonic stem cells into cardiomyocytes.[J] Circ Res,2002; 91(3):189-201.
[2]尹青,赵昱,赵秀军,等.5-氮胞苷诱导体外培养的胚胎干细胞向心肌细胞分化.[J]基础医学与临床,2007；27(5)：549-552.
[3]HeschelerJ, Fleischmann BK, Lentini S, et al. Embryonic stem cells:a model to study structural and functional properties in cardiomyogenesis.[J] Cardiovasc Res,1997; 36 (2):149-162.
[4]Sachinidis A,Fleischmann BK, Kolossov E,et al. Cardiac specific differentiation of mouse embryonic stem cells.[J] Cardiovasc Res,2003; 8 (2):278-291.
[5]Zhu DY, Qu LH, Zhang XN,et al. Icariin-mediated modulation of cell cycle and p53 during cardiomyocyte differentiation in embryonic stem cells.[J] Eur J Pharmacol,2005;514(2-3):99-110.
[6]Zhu DY, Lou YJ. Inducible effects of icariin, icaritin, and desmethylicaritin on directional differentiation of embryonic stem cells into cardiomyocytes in vitro.[J] Acta Pharmacologica Sinica,2005; 26 (4):477-485.
[7]Ding L, Liang XG, Hu Y. Involvement of p38MAPK and reactive oxygen species in icariin-induced cardiomyocyte differentiation of murine embryonic stem cells in vitro.[J] Stem Cells Dev,2008; 17(4): 751-760.
[8]王芳洁,易岂建,郭鹏飞.小鼠胚胎干细胞分化为心肌细胞的体外实验.[J]第四军医大学学报,2009；39(9)：808-811.
[9]马晓辉,高长青,李伯君,等.骨髓间充质干细胞移植治疗急性心肌梗死的实验研究.[J]中华医学杂志,2009；89(15)：1067-1070.
[10]Hare JM, Traverse JH, Henry TD, et al. A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Intravenous Adult Human Mesenchymal Stem Cells (Prochymal) After Acute Myocardial Infarction.[J] Am Coll Cardiol,2009;54(24):2277-2286.
[11]汪朝晖,冼绍祥,杨忠奇,等.人参总皂苷诱导骨髓间充质干细胞分化为心肌细胞的实验研究.[J]广州中医药大学学报,2006；23(2)：100-103.
[12]杨忠奇,冼绍祥,汪朝晖,等.三七总皂苷对骨髓间充质干细胞分化为心肌样细胞的作用.[J]中药新药与临床药理,2006；17(4)：239-242.
[13]冼绍祥,杨忠奇,汪朝晖,等.黄芪甲苷体外诱导骨髓间充质干细胞分化为心肌样细胞的实验研究.[J]广州中医药大学学报,2007；24(1)：37-40.
[14]杨庆有,冼绍祥,孙慧茹,等.黄芪含药血清诱导骨髓间充质干细胞分化为心肌样细胞的实验研究.[J]辽宁中医杂志,2008；35(6)：832-834.
[15]谢玲玲.淫羊藿苷诱导骨髓间充质干细胞分化心肌样细胞的实验研究[D].广州：广州中医药大学中西医结合基础专业,2008.
[16]刘韶英.淫羊藿苷对骨髓间充质干细胞增殖及向心肌细胞分化的影响[D].北京：北京中医药大学中西医结合临床专业,2008.
[17]Leri A, Kajstura J, Anversa P. Cardiac stem cells and mechanisms of myocardial regeneration.[J] Physiol Rev, 2005; 85(4):1373-1416.
[18]Itzhaki-Alfia A, Leor J, Raanani E, et al. Patient characteristics and cell source determine the number of isolated human cardiac progenitor cells.[J] Circulation,2009; 120(25):2559-2566.
[19]Smits AM, van Vliet P, Metz CH, et al. Human cardiomyocyte progenitor cells differentiate into functional mature cardiomyocytes:an in vitro model for studying human cardiac physiology and pathophysiology.[J] Nat Protoc,2009; 4(2):232-243.
[20]魏强,赵强,魏来,等.成人心肌干细胞的体外培养纯化与鉴定.[J]中国临床医学,2009；16(2)：187-190.
[21]陆东风,吴昊,黄璟,等.新生SD大鼠心肌干细胞的体外分离培养与鉴定.[J]南方医科大学学报,2006；26(11)：1629-1632.
[22]姜宏,施广飞.心肌干细胞培养和纯化的实验方法研究.[J]现代生物医学进展,2009；9(1)：33-35.
[23]姜宏,施广飞.5-氮胞苷诱导心肌组织中c-kit+干细胞分化的实验研究.[J]中国临床药理学与治疗学,2008；13(9)：996-1001.
[24]Tomita Y, Makino S, Hakuno D, et al. Application of mesenchymalstem cell-derived cardiomyocytes as bio-pacemakers:current s tatus and problems to be solved.[J] Med Biol Eng Comput,2007;45(2):209-220.